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a b s t r a c t
Objectives: Estimation of the incidence of nephropathy as well as potential risk factors involved in its onset
in a cohort of patients with type 1 diabetes who were followed from diagnosis.
Methods: We studied 716 patients, who were followed for a mean (standard deviation [SD]) of 10.1 (SD:
5.3) years. We analyzed the inﬂuence of demographic characteristics and levels of glycated hemoglobin
(A1C), lipids and blood pressure during the course of the disease by univariate and multivariate survival
methods.
Results: The cumulative incidence of nephropathy was 2.6%, 6.3% and 11.9% at 5, 10 and 15 years of evo-
lution, respectively. The factors associated with increased risk for nephropathy were systolic blood pres-
sure and A1C levels. An increment of 10 mm Hg in systolic blood pressure increases the risk by 36%, and
an increment of 1% in A1C levels raises the risk by 13% at 5 years since onset and 68% at 10 years, and it
doubles the risk at 15 years. Women have higher risk than men (hazard ratio 1.79; p=0.024).
Conclusions: Our study suggests that female gender and high levels of A1C and systolic blood pressure
throughout the course of the disease are the main factors associated with an increased risk for devel-
opment of nephropathy in patients with type 1 diabetes mellitus.
© 2015 Canadian Diabetes Association.
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r é s u m é
Objectifs : Estimation de l’incidence de la néphropathie ainsi que les facteurs de risque potentiels impliqués
dans son apparition dans une cohorte de patients atteints de diabète de type 1 qui ont été suivis d’un
diagnostic.
Méthodes : Nous avons étudié 716 patients, qui ont été suivis pendant une durée moyenne (écart type
[]) de 10,1 (SD: 5.3) ans. Nous avons analysé l’inﬂuence des caractéristiques démographiques et des niveaux
d’hémoglobine glyquée (A1C), les lipides et la pression artérielle au cours de l’évolution de la maladie
par la survie univariée et multivariée méthodes.
Résultats : L’incidence cumulée de la néphropathie a été de 2,6%, 6,3% et de 11,9% à 5, 10 et 15 années
d’évolution, respectivement. Les facteurs associés à un risque accru de néphropathie étaient la pression
artérielle systolique et les niveaux d’A1C. Une augmentation de 10 mm Hg dans la pression artérielle
systolique augmente le risque de 36%, et une augmentation de 1% du taux d’HbA1c augmente le risque
de 13% à 5 ans depuis le début et 68% à 10 ans, et il double le risque à 15 ans. Les femmes ont un risque
plus élevé que les hommes (hazard ratio 1,79; p=0,024).
Conclusions : Notre étude suggère que le sexe et des niveaux élevés de femmes A1C et la pression artérielle
systolique pendant toute la durée de la maladie sont les principaux facteurs associés à un risque accru
de développement de la néphropathie chez les patients avec diabète de type 1.
© 2015 Canadian Diabetes Association.
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Introduction
Diabetic nephropathy is one of the most serious complications
in patients with type 1 diabetes. It includes several stages,
microalbuminuria being an early marker of structural renal disease.
The prevalence of microalbuminuria ranges from 12% to 25% at
10 years of evolution (1) and from 30% to 40% after 20 years (2,3).
Of patients with microalbuminuria, half evolve to more advanced
stages while 50% to 60% return to normal albuminuria values (4).
Although the incidence of this complication appears to be decreas-
ing (5), it remains themost common cause of end stage renal disease
and increases cardiovascular risk for these patients (6–9).
Several risk factors have been associated with the onset of
nephropathy, apart from glycemic control (10), such as glycemic vari-
ability (11,12), duration of the diabetes, hypertension (13), smoking
(14), plasma lipid levels (15–17), body mass indexes (BMIs) (18)
and genetic predisposition. Contradictory data have been pub-
lished regarding factors, such as sex (19) or age at diagnosis (20),
with most of the studies referring to pediatric populations.
The objectives of this study were to estimate the risk for
nephropathy in its various phases and to assess the variables
related to its onset and progression in a cohort of patients who had
type 1 diabetes; no limits were placed on age at onset, and the
patients had been followed since diabetic onset in a longitudinal
study.
Methods
This was an observational, retrospective follow-up study. The sub-
jects of the study were patients with onset of type 1 diabetes
between January 1990 and December 2008 who were treated in the
Navarra Hospital Complex between January 1990 and December
2010. The cohort included 716 patients. The regional Ethical Review
Board of Navarra approved this study.
Type 1 diabetes was diagnosed according to the clinical crite-
ria recommended by theWorld Health Organization (21). The clini-
cal diagnostic criteria were those previously validated by Molback
(22).
According to the medical protocol followed, all patients had at
least 1 scheduled outpatient appointment per year. The informa-
tion for the study was obtained from the electronic health records
of the Navarre Health Service. We gathered information about age,
sex, GAD65 and IA2 autoantibodies at onset for all patients. At the
initial visit and for every visit through follow up, we included
weights; BMIs, systolic blood pressure (SBP) and diastolic blood pres-
sure (DBP) (BP was obtained after patients rested for 5 minutes in
the sitting position); smoking status and analytic data, such as lipid
proﬁles and A1C levels. When patients had more than 1 determi-
nation of these covariates in a year, we computed the arithmetic
mean in the case of continuous variables, whereas for the cat-
egoric variables, we chose the value that had lasted longest during
that year.
Urinary albumin excretion was measured in each patient at least
once a year by nephelometry (Beckman Coulter, Sharon Hill, Penn-
sylvania, US) between 1990 and 2006 and by immunoturbidimetry
(Roche Diagnostics, Risch-Rotkreuz, Switzerland) between 2006 and
2010. In line with current American Diabetes Association recom-
mendations, microalbuminuria was deﬁned as urinary albumin
excretion rates of 20 to 200 mg/g in the ﬁrst morning urine test in
at least 2 of 3 consecutive samples. The minimum time between
samples was 3 months. Macroalbuminuria was deﬁned as albumin
excretion rates >200 mg/g. Kidney failure was deﬁned by values of
creatinine ≥1.2mg/dL or calculation of creatinine clearance <60mL/
min/1.73m2 using the Cockcroft-Gault formula at 2 consecutive study
visits. For total risk estimates, we considered nephropathy as pre-
senting at least 1 of the renal outcomes, i.e. as presenting
microalbuminuria (including reverted microalbuminuria) or/and
macroalbuminuria or/and kidney failure. Possible causes of kidney
disease other than diabetes were ruled out.
Between 1990 and 1997, A1C levels were measured by several
techniques: Abbott IMX (Abbott Laboratories, Lake Bluff, Illinois,
USA); Ciba Corning Glycomat (Ciba Corning Diagnostics, Walpole,
Massachusetts, USA); and Merck (Merck Millipore, Darmstad,
Germany) and Menarini (Menarini Diagnostics, Florence, Italy) high
pressure liquid chromatography (HPLC); after 1997, by HPLC (Adams
A1C HA, Menarini Diagnostics, Florence, Italy); reference range: 4.1%
to 6.2%. In 2005, the laboratory of the hospital complex obtained
the level II certiﬁcation of traceability of the Diabetes Control and
Complications Trial (DCCT) Reference Method through the National
Glycohemoglobin Standardization Program. Previous A1C level deter-
minations were standardized to the DCCT reference range (4.05%
to 6.05%) (23).
Cholesterol, HDL cholesterol and triglycerides (TGs) were mea-
sured by GPO-PAP (Roche Diagnostics). LDL cholesterol was calcu-
lated by using the Friedewald equation. Serum creatinine was
measured by the Jaffé method (Roche Diagnostics). Determination
of anti-GAD and anti-IA2 antibodies was performed using the RIA
technique (Medipan Diagnostica, Blankenfelde-Mahlow, Germany).
This study was supported by a grant from the Carlos III Insti-
tute of Health (PI10/02715) and a grant from the Government of
Navarre (53/2008)
Statistical analysis
The characteristics of the patients at disease onset were sum-
marized using frequencies and percentages, means and standard
deviations (SDs). The cumulative incidence of nephropathy for the
global sample was estimated and graphed using Kaplan-Meier
curves, and conﬁdence intervals based on the cumulative hazard
were derived for 3 time points of the follow up: 5, 10 and 15 years
since onset. Data were right-censored when no nephropathy event
occurred throughout follow up or because of loss to follow up or
death.
The effects of demographic-, clinical- and analytic-related vari-
ables on nephropathy were assessed through a 2-step procedure.
First, univariate Cox-proportional regressionmodels were ﬁtted using
the covariates as ﬁxed variables (characteristics at diabetes onset)
and as time-dependent variables (characteristics during follow-
up). The proportional assumption implicit in the Cox-regression
modelling was assessed using weighted residuals and, when vio-
lated, an interaction term with time was included in the models.
The possible modifying effect of age group was also evaluated and,
when appropriate, models were adjusted or stratiﬁed by age group.
This step, which was complemented graphically with plots of the
stratiﬁed cumulative incidence curves obtained with the Kaplan-
Meier method, provided the signiﬁcation of the covariates and the
estimation of the hazard ratios. In the second step, a multivariate
regression model was ﬁtted with the variables that had turned out
to be signiﬁcant or marginally signiﬁcant (p<0.1) in the previous
step.
A p value of <0.05 was considered statistically signiﬁcant. All
analyses were performed using the R statistical package, v. 2.13
(R Foundation for Statistical Computing. Vienna, Austria).
Results
We followed 716 patients with type 1 diabetes from onset: 280
patients with onset younger than 15 years of age and 436with onset
older than 15. The mean (SD) follow upwas 10.1 (5.3) years, ranging
from 2 (those with onset in 2008) to 21 years (those with onset in
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1990). Demographic and clinical characteristics at onset of the
disease are given in Table 1.
At follow up, 60 patients developed nephropathy (8.4%). Pos-
sible causes of kidney disease other than diabetes were ruled out
for these patients. Most of them (53 patients) ﬁrst had
microalbuminuria, and of these, 19 patients (35.8%) reverted to
normoalbuminuria, 30 patients (56.7%) remained in
microalbuminuria and 4 patients (7.5%) progressed to
macroalbuminuria. Of the 19 patients who reverted to
normoalbuminuria, more than half (68%) reverted during the ﬁrst
year followingmicroalbuminuria diagnosis, and all of them reverted
within a 5-year period. The mean (SD) age at diagnosis of
microalbuminuria was 27.7 (13.8) years of age, and only 9 of the
53 patients (17%) experiencedmicroalbuminuria when younger than
15. Four patients developed macroalbuminuria, and 3 developed
kidney failure with no prior microalbuminuria. No cases of
macroalbuminuria or renal failure occurred at ages younger than
15, and themean ages (SD) at diagnoses of these complications were
33.3 (10.2) years and 45.3 (18.3) years, respectively. The cumula-
tive incidence of nephropathy was 2.6% (1.4 to 3.8) at 5 years, 6.3%
(4.2 to 15.1) at 10 years and 11.9% (8.5 to 15.1) at 15 years (Table 2).
Regarding demographic characteristics, with respect to the risk
for nephropathy, age at diabetes onset was marginally signiﬁcant
when comparing onset at ages younger than 15 years versus onset
at ages older than 15 years (p=0.070), with a hazard ratio (HR)=0.63
for adults with respect to children. When comparing all age groups
together, a borderline signiﬁcance was obtained (p=0.055) (Figure
1a), the most remarkable result being the fact that the risk is lower
in the 30- to 44-year group (HR=0.36) and higher in the ≥45–year
group (HR=1.62) (Table 3). Sex was signiﬁcant, with women having
a higher risk for nephropathy than men (HR=1.79; p=0.024). The
cumulative incidence at 15 years in males was 9.5 (95% CI: 5.3–
13.5), whereas in females it was 15.1 (95% CI: 9.4–20.4) (Figure 1b).
No ﬁndings were observed related to positivity of antibody levels
at onset for either IA2 or GAD. BMIs were not statistically signiﬁcant.
Figure 1. Cumulative incidence of nephropathy by sex and age group at onset.
Table 1
Demographic and clinical characteristics at onset of patients with onset between
1990 and 2008 in the Navarra Hospital Complex
Variable Total Patients
<15 years
Patients
≥15 years
Categoric
variables
n (%) n (%) n (%)
Sex Men 413 (58%) 154 (55%) 259 (59%)
Women 303 (42%) 126 (45%) 177 (41%)
Age group 0–9 134 (19%) 134 (48%) -
10–14 146 (20%) 146 (52%) -
15–29 246 (34%) - 246 (56%)
30–44 148 (21%) - 148 (34%)
≥45 42 (6%) 42 (10%)
HTA No 578 (98%) 200 (99%) 378 (96%)
Yes 14 (2%) 2 (1%) 12 (3%)
BMIqa over q97a 19 (3%) 4 (1.5%) 15 (4%)
q85-q97a 45 (8%) 4 (1.5%) 41 (11%)
below q85a 550 (89%) 236 (96.5%) 314 (85%)
Smoking No 442 (68%) 254 (100%) 188 (48%)
Ex smoker 31 (4%) 0 (0%) 31 (8%)
Yes 176 (27%) 1 (0%) 175 (44%)
GAD65
(<5 years)
No 112 (23%) 56 (30%) 56 (18%)
Yes 374 (77%) 128 (70%) 246 (82%)
IA2 (<5 years) No 235 (52%) 71 (395%) 164 (60%)
Yes 217 (48%) 109 (61%) 108 (40%)
Continuous
variables
N Mean (SD) Mean (SD) Mean (SD)
Years of
follow up
10.1 (5.3) 10.0 (5.6) 10.3 (5.2)
BMI (kg/m2) 614 20.2 (4.2) 16.8 (2.8) 22.4 (3.5)
SBP (mm Hg) 591 114.2 (14.5) 110.9 (12.9) 116.0 (15.0)
DBP (mm Hg) 592 68.7 (10.9) 66.4 (11.4) 69.9 (10.4)
LDL (mg/dL) 549 119.1 (39.9) 111.7 (32.2) 124.2 (43.8)
HDL (mg/dL) 561 48.9 (15.1) 53.4 (14.0) 45.8 (15.1)
Triglycerides
(mg/dL)
605 118.7 (141.4) 85.3 (55.4) 140.7 (173.2)
A1C (%) 549 10.8 (2.6) 10.4 (2.2) 11.1 (2.82)
A1C, glycated hemoglobin; BMI, body mass index; DBP, diastolic blood pressure; HTA,
Health Technology Assessment; LDL, low-density lipoprotein; SBP, systolic blood
pressure.
a BMIq: Proportions calculated according to age-speciﬁc BMI quantiles.
Table 2
Cumulative incidence (95% CI) of total nephropathy by subtype and for age group
at onset, after 5, 10 and 15 years since onset
Time since onset
5 years (%) 10 years (%) 15 years (%)
Nephropathy 2.6 (1.4–3.8) 6.3 (4.2–15.1) 11.9 (8.5–15.1)
Microalbuminuria 2.5 (1.3–3.6) 6.1 (4.0–9.1) 10.6 (7.4–13.6)
Permanent
microalbuminuria
1.1 (0.3–1.9) 2.2 (0.9–3.4) 4.4 (2.2–6.5)
Macroalbuminuria 0 0 2.3 (0.5–4.2)
Kidney failure 0.1 (0–0.4) 0.1 (0–0.4) 1.7 (0.1–3.2)
Nephropathy by age
group at onset
0–9 years 2.5 (0.0–5.3) 9.1 (2.7–15.1) 14.8 (5.7–23.1)
10–14 years 5.0 (1.3–8.5) 10.0 (4.3–15.4) 13.3 (6.1–20.1)
15–29 years 2.1 (0.3–3.9) 4.7 (1.8–7.6) 10.1 (5.3–14.8)
30–44 years 0.7 (0.0–2.1) 1.8 (0.0–4.3) 5.3 (0.0–12.2)
≥45 years 4.8 (0–11.0) 9.8 (0.0–20.4) 39.2 (1.6–62.5)
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In patients with onset at ages older than 15 years, there is a trend
toward higher risk in smokers than in nonsmokers (or ex-smokers),
considering smoking status at onset (HR=1.90, p=0.118) and as a
time-dependent variable during follow up (HR=1.87; p=0.105).
Arterial BP and laboratory values at onset did not have a pre-
dictive value for nephropathy; low-density cholesterol (LDL) cho-
lesterol was the only variable found to be signiﬁcant, with higher
levels associatedwith higher risk (HR=1.08; p=0.023). However, using
the values recorded in the visits during the follow ups, all of them
except high-density lipoprotein (HDL) cholesterol showed some pre-
dictive value, at least marginally; an increment of 10 mg/dL in TGs
increased the risk by 3% (p=0.073). For the A1C and LDL choles-
terol levels, the HR was not constant, but it increased with time.
An increment of 1% in the A1C levels increased the risk for nephropa-
thy by 13% at 5 years since onset and by 68% at 10 years, and it
doubles the risk at 15 years. Similarly, an increment of 10 mg/dL
in LDL cholesterol levels increased the risk by 2% at 5 years, 14%
at 10 years and 27% at 15 years. Along the same lines, an incre-
ment of 10mmHg in SBP increased the risk of nephropathy by 62%
(p=0.015), and an increment of 10mmHg in DBP is related to a 32%
rise (p=0.075).
When the risk factors listed above were considered together in
the multivariate Cox proportional model, the factors that remained
independently related to nephropathy were SBP and A1C levels
(Table 4). Sex and age, included for adjustment, were marginally
signiﬁcant: being a woman was associated with higher risk for
nephropathy, and having diabetes onset between 30 and 44 years
was associated with lower risk. An increment of 10 mm Hg in SBP
increased the risk for nephropathy by 36%, and an increment of 1%
in the A1C levels increased the risk for nephropathy by 9% at 5 years
since onset, 63% at 10 years and doubled the risk at 15 years.
Discussion
In this study, we characterized the incidence of kidney disease
in patients of all ages with type 1 diabetes, children and adults, fol-
lowed since they had been diagnosed. These characteristics make
this study original in respect to previously published studies. The
cumulative incidence at 5, 10 and 15 years since diabetes onset was
2.6%, 6.3% and 11.9%, respectively. Incidence studies published so
far have shown disparate data, to a great extent derived from dif-
fering characteristics of patients regarding age, risk factors and dura-
tion of diabetes but, overall, they point to a downward trend in the
incidence of late complications of diabetes compared to that
described in previous decades (15,24–27). The relatively low inci-
dence of nephropathy we found is in line with this downward trend,
which is likely to be the result of the implementation of better and
more successful control strategies for patients with diabetes.
With respect to the course of kidney disease, regression to
normoalbuminuria was the most common renal outcome, occur-
ring in 35.8% of cases of microalbuminuria in the cohort. This
normoalbuminuric regression is similar to that found in the Epi-
demiology and Prevention of Diabetes (EURODIAB) study (18) and
that obtained by Perkins et al (28). Little is known about the
clinical signiﬁcance of these data. Progression to macroalbuminuria
in our patients (7.5%) was similar to the rate observed by Raile et al
(13) but less than that described by the EURODIAB group (14%) or
the Epidemiology of Diabetes Interventions and Complications (EDIC)
study (10) by de Boer et al (3) and by Hovind et al (5). The per-
centage of patients who develop more advanced renal disease
without having prior microalbuminuria (12%) is lower than that
reported by the DCCT/EDIC study (24%).
The increase in A1C levels is the most conﬁrmed risk factor for
kidney disease in both pediatric and adult populations. The DCCT
demonstrated the beneﬁt of intensive treatment of hyperglyce-
mia, which is maintained even in the long term (10). Thus, levels
below 8% are associated with regression of microalbuminuria to
normoalbuminuria and values less than 7% would be set as a target
for reducing the risk for glomerular ﬁltration decrease (7). Glyce-
mic variability could also be involved in the pathogenesis of this
complication (11,12). Our ﬁndings support the importance of gly-
cemic control in the prevention of kidney disease, with relatively
high HR estimates for A1C level variations, and the results suggest
that the increase in the risk for nephropathy associated with poor
Table 3
Association of covariates with risk of nephropathy using univariate Cox regression
models
Variable Category/units At onset of diabetes
HR (CI 95%) p
Demographic characteristics
Sex Males Reference
Females 1.79 (1.08–2.99) 0.024
Age group <10 years Reference
10–14 years 0.94 (0.46–1.94)
15–30 years 0.59 (0.30–1.19) 0.055
30–44 years 0.36 (0.13–1.00)
≥45 years 1.62 (0.62–4.23)
Positivity antibody levels at onset
GAD No Reference
Yes 1.19 (0.48 - 2.92) 0.454
IA2 No Reference
Yes 1.37 (0.64–2.92) 0.417
Physical examination and laboratory
values as time-dependent variables
Tobacco (≥15 years) Non/exsmoker Reference
Smoker 1.87 (0.88–3.94) 0.105
BMIq <q85 Reference
≥q85 0.61 (0.30–1.23) 0.149
SBP per 10 mm Hga 1.62 (1.05–1.52) 0.015
DBP per 10 mm Hga 1.32 (0.97–1.79) 0.075
TG per 10 mg/dLa 1.03 (1.01–1.05) 0.073
HDL per 10 mg/dLa 0.87 (0.72–1.05) 0.140
LDLb LDL 10 mg/dLa 0.91 (0.74–1.11) 0.337
LDLa timea 1.02 (1.00–1.04) 0.018
A1Cb A1C 0.74 (0.49–1.11) 0.136
A1Catime 1.08 (1.04–1.13) <0.001
A1C, glycated hemoglobin; BMI, body mass index; DBP, diastolic blood pressure; HDL,
high-density lipoprotein; HTA, Health Technology Assessment; LDL, low-density lipo-
protein; SBP, systolic blood pressure; TG, triglycerides.
a Hazard ratios for covariates SBP, DBP, HDL cholesterol, TG and LDL cholesterol
were estimated for 10-unit increments (HR per increments of 10 mm Hg in SBP and
DBP, and per increments of 10 mg/dL in HDL cholesterol and LDL cholesterol and
TGs).
b When interaction terms with time are signiﬁcant (for A1C and LDL choles-
terol), HRs are time dependent: For A1C, HR(t)=0.74*1.08t; for LDL cholesterol:
HR(t)=0.91*1.02t.
Table 4
Multivariate Cox-proportional regression model results for nephropathy
Variable Category HR (CI 95%) p
Sex Males Reference
Females 1.56 (0.86–2.83) 0.144
Age at onset <10 years Reference
10–14 years 0.68 (0.29–1.61)
15–29 years 0.65 (0.30–1.40) 0.149
30–44 years 0.25 (0.08–0.77)
≥45 years 0.53 (0.15–1.81)
SBP per 10 mm Hga 1.36 (1.11–1.67) 0.004
A1C A1C tb 0.69 (0.45–1.06) 0.078
A1Ca tb 1.09 (1.04–1.13) <0.001
A1C, glycated hemoglobin; HR, hazard ratio; SBP, systolic blood pressure; t, time.
a The HR for SBP was evaluated according to increments of 10 mm Hg.
b The HR for A1C varies with time: the longer the follow up (t), the higher the
risk: HR(t)=0.69*1.09t (for t=5 years: HR=1.06; for t=10 years: HR=1.63; for t=15 years:
HR=2.51).
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glycemic control becomes greater as the duration of diabetes
increases.
Without reaching statistical signiﬁcance, our results point to an
increased risk for nephropathy in patients with disease onset before
the age of 15 compared to patients whose onset occurred in older
age. From previous studies we have learned that there seems to be
a lower risk in patients with onset before the age of 10 (27) and
before the age of 5 (29), assuming that the prepubertal duration
of diabetes contributes less than the postpubertal duration to the
risk for complications. However, in our cohort, the risk was lower
in the 30- to 45-year age group, a ﬁnding not previously described.
One explanation for this could be better glycemic control observed
in this group of patients, who during the ﬁrst 5 years after onset
maintained A1C levels below 7.5% (30). Moreover, it could be a cohort
effect regarding the incidence of nephropathy related to the advances
in diabetes regimens. In order to study this possible cohort effect,
we classiﬁed the cohort into 5-year period bases depending on their
diagnoses with type 1 diabetes (1990 to 1994; 1995 to 1999; 2000
to 2004; 2005 to 2008), and then we compared the cumulative inci-
dence with the follow-up information concerning these 4 cohorts.
The results showed no differences among these 4 cohorts.
Differences in risk for nephropathy between sexes have been
attributed to hormonal, environmental and genetic factors (15), but
studies have not been conclusive. Harjutsalo et al (31) reported a
higher incidence of nephropathy in males, but the Finnish Diabe-
tes Register (27) showed no difference between sexes. In our study,
women show higher risk for developing kidney disease than men,
which could possibly be due to poorer glycemic and SBP control
in women, because the signiﬁcance of sex disappears when adjust-
ing for these variables. This ﬁndingwould point to the need for closer
glycemic control and attention to risk factors in females.
The cumulative incidence of nephropathy in this study was not
affected by BMI. A positive relationship was previously described
between body weight and risk for onset and progression of
microalbuminuria tomacroalbuminuria, suggesting that a lower level
of abdominal fat is a protective factor for kidney damage (18).
Smoking seems to be related to nephropathy but with mar-
ginal signiﬁcance. Mechanisms such as glomerular hyperﬁltration,
proximal tubule damage and tissue hypoxia would be the mecha-
nisms involved, although their importance has been questioned by
some authors (14,18,32).
Other factors must also be considered when studying the risk
for subsequent development of nephropathy. Publications have
shown that BP elevations and absence of nocturnal BP decrease
(33,34) might be involved in the early stages of the disease, both
in the appearance and in the development of microalbuminuria.
Some studies establish BP levels below which regression of
microalbuminuria is more likely to occur (28), but the inﬂuence of
pharmacologic intervention in this evolution is not clear. Accord-
ing to our results, each 10mmHg increase in SBP increases the risk
for nephropathy by 62%, and an increase of 10 mm Hg in DBP
increases the risk by 32%. This data would support the concept of
the role that increased glomerular pressure would have in the patho-
physiology of this type of angiopathy.
Data involving alterations of lipid levels in the development and
progression of nephropathy are limited, most of them derived from
cross-sectional studies (16). The measurements of the levels of the
various lipid fractions (LDL cholesterol, non-HDL cholesterol, tri-
glycerides and lowHDL cholesterol) have been suggested to be useful
in identifying patients with increased risk for progression of
microalbuminuria (4,15,16,35). The association with dyslipidemia
is more marked in patients with macroalbuminuria (36). In our
cohort, regarding lipid levels at diagnosis, LDL cholesterol is the one
that seems to correlate signiﬁcantly with the onset of nephropa-
thy. TG levels also seem to correlate but did not reach statistical sig-
niﬁcance. However, according to our results, it appears that the
inﬂuence occurs through factors such as glycemic control. The
mechanism behind this relationship could be an endothelial dys-
function resulting from the increased lipid peroxidation as well as
from increased insulin resistance in patients with higher lipidic levels.
Some of the limitations of this study are noteworthy. First, the
small number of patients who developed complications limits the
statistical power to identify predictive factors of nephropathy and
precludes analysis of the variables related to the evolution into more
severe stages of nephropathy. Second, the follow-up period was
limited to 20 years since onset, and it is from that time onward that
the higher incidence of this complication is expected. The main
strength of the study is that patients were followed since onset of
diabetes and, consequently, the cumulative incidence of nephropa-
thy at differing times (5, 10 and 15 years) are speciﬁc risk esti-
mates for those periods. Another positive feature of this study is
that clinical criteria and data are homogeneous for all patients
because all of them came from the same hospital.
Conclusions
In conclusion, our study suggests that several risk factors, pri-
marily A1C levels and higher SBP throughout the course of the
disease, in addition to LDL cholesterol levels and female gender, point
to increased risks for developing nephropathy after diagnosis. The
identiﬁcation of these factors may have therapeutic implications
in the follow up of these patients who have type 1 diabetes.
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